You are here

KRONİK BÖBREK YETMEZLİĞİ OLAN HASTALARDA TÜMÖR BELİRLEYİCİLERİNİN DEĞERLENDİRİLMESİ

Share

Journal Name:

Volume:

Publication Year:

Number:

Sayfa Aralığı:: 
42-46

Publication Language:

Abstract (Original Language): 
Literatürde bazı çalışmalarda kronik böbrek yetmezlikli hastalarda bir malignite olmamasına rağmen bazı tümör belirleyicilerinin arttığı gösterilmiştir. Bu çalışmada malignİtesi olmayan ve hepatit belirleyicileri negatif olan 36 prediyaliz, 42 hemodiyaliz (HD), 26 sürekli ayaktan periton diyalizi (SAPD) hastalarında ve 22 sağlıklı kontrolde farklı tümör belirleyicilerinden serum a-fetoproteİn (AFP), karsinoembriyojenik antijen (CEA), karbonhidrat antijen 125 (CA 125), karbonhidrat antijeni 19-9 (CA 19-9), karbonhidrat antijeni 15-3 (CA15-3), prostat spesifik antijen (PSA) seviyelerine bakıldı. Prediyaliz, hemodiyaliz ve periton diyalizi hastalarının ortalama serum CEA ve CA 19-9 düzeyleri kontrol grubuna göre yüksek bulundu. Ayrıca SAPD hastalarında CA 125 düzeyi diğer gruplara ve kontrol grubuna göre yüksekti. Serum AFP, CA 15-3 ve PSA düzeyleri bütün gruplarda benzerdi. Ancak tüm tümör belirleyicilerinin bütün hastalarda normal laboratuvar sınırları içerisinde olduğu görüldü. Serum tümör belirleyicilerinin kronik böbrek yetmezliği hastalarında tanısal öneminin olmadığı görülmüştür ve malignite şüphesi olmayan kronik böbrek yetmezlikli hastalarda araştırma projeleri dışında çalışılmasına gerek yoktur.
Abstract (2. Language): 
The assessment of tumor markers in the patients with ehronic renal failure. In thc literatüre some studics showed that serum levels of some tumor markers inerease in patients with ehronic renal failure, despite the absence of malignaııcy. The aim of thİs study was to İnvestigate serum levels of different tumor markers such as alpha fetoprotein (AFP), carcinoembryonic antigen (CEA), cancer antigen 125 (CA 125), carbohydrate antigen 19-9 (CA 19-9), carbohy-drate antigen 15-3 (CA15-3), prostaıic specifie antigen (PSA) in 36 predİalysis, 42hemodialy-sis (HD) and 26 conlinuous ambulatory peritoneal dialysİs (CAPD) patients as well as 22 he-atthy controls who had not malignaney and negative hepatitis markers profile wcre enrolled. The mcan CEA and CA 19-9 levels were found to be higher than the control group in predİalysis patients, HD patient and CAPD patient groups. In addition serum CA 125 level in CAPD patients group was found higher than the other groups. Serum AFP, CA 15-3 and PSA levels were similar in ali groups. Howcver ali serum tumor markers levels vvere in normal rau-ge İn al! the patients. To conelude, serum tumor markers do not have diagnostic significance in patients with ehronic renal failure. These markers should not be studied out of research projects in this patient population wİthout malignaney suspİcion.

REFERENCES

References: 

1. Arican A. Özdemir N, Sezer S, Etten Y, Güz G, Turan M: Tumor markers in hemodiaiysis patients. Transplant Proc 31:3367(1999).
2. Arik N. Adam B, Akpolat T, Hasil K, Tab;ık S: Serum tumour markers in renal failure. Int Urol Nephrol 28:601 (1996).
3. Bates SE: Clinical applieations of serum tumor markers. Ann lntern Mcd 115:623 (1991).
4. Betjcs MGH, Bos HJ, Krediet RT, Arizs L: The mesot-
heliaî celi in CAPD effluent and their relatioıt to peritoni-fis incidence. PeritDial Int 11:22 (1991).
5. Bouts AHM, Groothoff JW, van Amstel SP, Zweers MM, Davın J, Krediet RT: Dialysate cancer antigen 125 [evels in childten trcated with peritoneal dialysis. Adv PeritDial 16:328 (2000).
6. Cases A, Filella X, Molino R, Ballesla AM, Lopez-Ped-ret J, Revert L: Tumor markers in ehronic renal failure and hemodiaiysis patients. Neplıron 57:183 (1991).
7. Erdem F, Alper D: Akciğer kanserlerinde tümör belirleyicileri. T KlinTıp Bilimleri 15:418 (1995).
8. Fiieüa X, Cases A, Molina R, Jo J, Bedini JL, Revert L: Tumor markers in patients wilh ehronic renal failure. Int JBioi Markers 5:85 (1990).
9. Jacobs L, Brunncr FP, Brynger H, Chantler C, Hathway RA, Krema P: Malignant diseases in patients trcated by dialysis and transplantation in Europe. Transplant Proc 13:729(1981).
10. Kadayjfçı A, Benekli M, Savaş C: Tümör belirleyicileri. Türkiye Tıp Dergisi 1:273 (1994).
11. Kashiwabara K, Nakamura H, Yagyu H, Kishi K, Matsu-oka T, Esaki T: Changes in squamous celi carcinoma-re-lated antigen levels before and after hemodiaiysis in rela-tion to the model of dialyzer employed. lntern Med 39:291 (2000).
12. Maisonneuve P, Agodoa L, Geilert R, Stewart JH, Buci-anti G, Lowentels AD: Cancer in patients on dialysis for end-stage renal disease: an international coltaborative study. Lancet 354:93 (1999).
13. Ncwstead CG: Cancer risk in patients on dialysis. Lancet 354:90(1999).
14. Odagiri E, Jibiki K, Takeda M, Sugimura M, Iv/achİka C, Abe Y: CEA, AFP, Squamous celi carcinoma-reiated antigen, ncuron-specific enolase, CA 125, CA 19-9, CA 15-3 inuremie patients. Am J Nephrol 11:363 (1991).
15. Polenakovic M, Sikole A, Dzikova S, Polenakovic B, Gelev S: Acquired renal eystic disease and tumor markers in ehronic hemodiaiysis patients. Int J Artif Organs 20:96 (1997).
16. Port FK, Ragheb NE, Schwartz AG, Hawthornc VM: Neoplasms in dialysis patients: a population based study. Am J Kidney Dis 24:119 (1989).
17. Oucntmeier A, Schlag P, Gelsen HP, Sehmidl-Gayk H: Elavuation of CA 125, as a tumor for gastric and coîorec-tal cancer in comparison to CEA and CA 19-9. Eur J SurgOncol 13:197 (1987).
18. Salem M, İvanovich P, Mujaİs S: End slage renal disease and malignaney. Int J Artif Organs 15:644 (1992).
19. Sasagawa 1, Nakata T, Hashimoto T, Ishigooka M, Ka-bota Y, Hirano K: Serum prostatic acid phosphatase, gamma-seminoprotein and prostatic specifıc antigen in hemodiaiysis patients. Urol Int 48:181 (1992).
20. Tenertolle MG, Park RC: Early deteetion of ovarian cancer. Cancer JCIin 45:71 (1995).
21. Van Dongen JA: Tumor markers: a tool for elinicians. Pattı Biol 41:27 (1993).
22. Visser CE, Brouwer-Stcenbergen JJ, Betjes MGH, Koo-men GC, Beelen RH, Krediet RT: Cancer antigen 125: A bulk marker for the mesothelial ınass in stable peritoneal dialysis patients. Nephrol Diaİ Transplant 10:64 (1995).

Thank you for copying data from http://www.arastirmax.com